ALXO Stock Price, ALX Oncology Holdings . Quote, Chart

Market Summary

USD16.62-0.32

Market Closed

-1.89%

ALXO Alerts

1 major insider sales recently.

ALXO Stock Price

View Fullscreen

ALXO RSI Chart

ALXO Valuation

Market Cap

833.5M

Price/Earnings (Trailing)

-5.18

Price/Sales (Trailing)

689.06

EV/EBITDA

-5.18

Price/Free Cashflow

-6.33

ALXO Price/Sales (Trailing)

ALXO Profitability

EBT Margin

-10441.46%

Return on Equity

-84.76%

Return on Assets

-66.3%

Free Cashflow Yield

-15.79%

ALXO Fundamentals

ALXO Revenue

Revenue (TTM)

1.2M

ALXO Earnings

Earnings (TTM)

-160.8M

Earnings Growth (Yr)

-48.07%

Earnings Growth (Qtr)

10.82%

Breaking Down ALXO Revenue

Last 7 days

-1.5%

Last 30 days

55.0%

Last 90 days

13.1%

Trailing 12 Months

171.6%

How does ALXO drawdown profile look like?

ALXO Financial Health

Current Ratio

5.24

Debt/Equity

0.05

Debt/Cashflow

-13.52

ALXO Investor Care

Shares Dilution (1Y)

22.73%

Diluted EPS (TTM)

-3.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	4.4M	3.7M	2.4M	1.2M
2019	0	3.0M	3.9M	4.8M
2018	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ALX Oncology Holdings Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	pons jaume	acquired	25,587	0.99	25,846	president & cso
Apr 16, 2024	pons jaume	sold	-710,195	14.2039	-50,000	president & cso
Apr 04, 2024	pons jaume	sold	-223,036	11.1518	-20,000	president & cso
Mar 14, 2024	lettmann jason	bought	49,771	11.3117	4,400	chief executive officer
Feb 14, 2024	pinto shelly	acquired	-	-	15,000	svp, finance and cao
Feb 14, 2024	randolph sophia	acquired	-	-	30,000	chief medical officer
Feb 14, 2024	pons jaume	acquired	-	-	30,000	president & cso
Feb 14, 2024	garcia peter s	acquired	-	-	25,000	chief financial officer
Feb 14, 2024	lettmann jason	acquired	-	-	60,000	chief executive officer
Jan 04, 2024	pinto shelly	sold	-36,956	13.602	-2,717	svp, finance and cao

Which funds bought or sold ALXO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	added	2.2	-96,802	62,551	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	55.00	55.00	-%
Apr 30, 2024	Private Wealth Management Group, LLC	unchanged	-	-367	1,093	-%
Apr 29, 2024	Bradley & Co. Private Wealth Management, LLC	unchanged	-	-3,740	11,150	0.01%
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	66.38	21,000	107,000	0.01%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-1,055	3,144	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.58	-395,694	889,402	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-55.41	-78,000	39,000	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-30.94	-13,710	14,685	-%

Are Funds Buying or Selling ALXO?

Are funds buying ALXO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALXO

No. of Funds

ALXO Alerts

1 major insider sales recently.

Unveiling ALX Oncology Holdings Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	orbimed advisors llc	4.5%	2,255,000	SC 13G/A
Feb 14, 2024	redmile group, llc	9.6%	4,909,264	SC 13G/A
Feb 14, 2024	lsv associates, llc	2.7%	1,366,530	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Dec 20, 2023	lsv associates, llc	3.9%	1,950,004	SC 13D/A
Oct 16, 2023	redmile group, llc	9.6%	4,991,545	SC 13G
Oct 13, 2023	cormorant asset management, lp	5.28%	2,630,000	SC 13G
Feb 14, 2023	orbimed advisors llc	5.6%	2,266,000	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 10, 2022	wellington management group llp	2.77%	1,128,101	SC 13G/A

Recent SEC filings of ALX Oncology Holdings Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 02, 2024	DEFA14A	DEFA14A
Apr 23, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 18, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	4	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading
Mar 08, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to ALX Oncology Holdings Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

ALX Oncology Holdings Inc. News

Latest updates

ALX Oncology Holdings Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-	-	-	1.00	1.00	1.00	1.00	1.00	-
Operating Expenses	81.7%	18.00	10.00	11.00	6.00	9.00	4.00	5.00	-
S&GA Expenses	26.8%	6.00	4.00	3.00	1.00	1.00	1.00	1.00	-
R&D Expenses	127.9%	12.00	5.00	8.00	4.00	7.00	2.00	4.00	-
Interest Expenses	23.4%	0.00	0.00	0.00	0.00	-	-	-	-
Income Taxes	420.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Earnings Before Taxes	-83.2%	-18.59	-10.15	-11.31	-5.45	-7.75	-3.04	-4.19	-
Net Income	-84.4%	-18.77	-10.18	-11.33	-5.45	-8.84	-4.11	-5.18	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	10.2%	243	220	246	278	306	318	346	364	380	400	421	433	436	262	103	57.00	11.00	11.00
Current Assets	-5.2%	189	199	220	233	271	291	317	322	367	389	412	432	436	262	101	-	10.00	10.00
Cash Equivalents	14.4%	22.00	20.00	38.00	63.00	49.00	49.00	66.00	159	364	385	410	430	434	259	98.00	105	9.00	8.00
Net PPE	-0.8%	4.00	4.00	4.00	4.00	4.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	-	1.00	1.00
Liabilities	2.9%	53.00	51.00	33.00	38.00	43.00	31.00	30.00	20.00	17.00	15.00	16.00	14.00	6.00	10.00	12.00	12.00	11.00	2.00
Current Liabilities	2.4%	36.00	35.00	18.00	22.00	28.00	25.00	24.00	15.00	15.00	12.00	14.00	14.00	6.00	7.00	8.00	-	5.00	2.00
Long Term Debt	0.7%	10.00	10.00	10.00	9.00	9.00	-	-	-	-	-	-	-	-	3.00	4.00	-	5.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	-	-	-
LT Debt, Non Current	0.7%	10.00	10.00	10.00	9.00	9.00	-	-	-	-	-	-	-	-	3.00	4.00	-	5.00	-
Shareholder's Equity	12.4%	190	169	213	240	263	287	316	344	363	385	405	418	430	252	-	-	-	-
Retained Earnings	-10.3%	-486	-440	-389	-355	-325	-294	-259	-226	-201	-173	-148	-132	-118	-99.75	-89.57	-	-72.78	-53.54
Additional Paid-In Capital	10.8%	676	610	603	596	590	583	577	571	565	559	554	551	548	352	5.00	-	2.00	2.00
Shares Outstanding	21.4%	50.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	40.00	40.00	40.00	40.00	-	-	-	-	-	-
Float	-	-	-	161	-	-	-	173	-	-	-	960	-	1,500	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-27.3%	-39,678	-31,159	-31,711	-27,816	-20,668	-30,883	-16,998	-20,674	-17,488	-24,856	-20,622	-5,135	-13,615	-9,548	-6,163	-8,963	-2,874	-3,186	-	-
Share Based Compensation	-3.5%	6,721	6,964	6,237	6,351	6,295	6,207	5,836	5,501	5,686	4,191	2,237	1,800	1,743	689	2,853	151	75.00	86.00	-	-
Cashflow From Investing	-230.1%	-16,666	12,815	6,213	42,295	10,942	13,695	-76,132	-183,921	-4,518	-398	-	-7.00	-11.00	631	-	-10.00	62.00	-	-	-
Cashflow From Financing	53402.7%	59,166	-111	343	-107	9,494	-136	422	80.00	524	439	731	778	188,361	170,298	-769	104,991	5,927	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALXO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 141,795	$ 98,400	$ 60,170
General and administrative	28,483	29,036	23,385
Total operating expenses	170,278	127,436	83,555
Loss from operations	(170,278)	(127,436)	(83,555)
Interest income	10,649	4,278	91
Interest expense	(1,565)	(238)	(13)
Other income (expense), net	389	(22)	(7)
Loss before income taxes	(160,805)	(123,418)	(83,484)
Income tax (provision) benefit		(64)	21
Net loss	$ (160,805)	$ (123,482)	$ (83,463)
Net loss per share, basic	$ (3.74)	$ (3.03)	$ (2.07)
Net loss per share, diluted	$ (3.74)	$ (3.03)	$ (2.07)
Weighted-average shares of common stock used to compute net loss per share, basic	42,987,767	40,699,612	40,308,050
Weighted-average shares of common stock used to compute net loss per share, diluted	42,987,767	40,699,612	40,308,050

ALXO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,406	$ 48,822
Short-term investments	160,330	217,385
Prepaid expenses and other current assets	5,923	4,762
Total current assets	188,659	270,969
Property and equipment, net	3,589	3,889
Long-term investments	35,411	16,699
Other assets	14,894	14,932
Total assets	242,553	306,489
Current liabilities:
Accounts payable	8,591	8,073
Payable and accrued liabilities due to related party	$ 543	$ 1,650
Other Liability, Current, Related Party, Type [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Accrued expenses and other current liabilities	$ 26,867	$ 18,602
Total current liabilities	36,001	28,325
Term loan, non-current, net	9,639	9,389
Other non-current liabilities	7,201	5,311
Total liabilities	52,841	43,025
Commitments and contingencies (Note 13)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 49,951,989 and 40,861,386 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	50	41
Additional paid-in capital	675,678	589,735
Accumulated other comprehensive loss	256	(845)
Accumulated deficit	(486,272)	(325,467)
Total stockholders’ equity	189,712	263,464
Total liabilities and stockholders’ equity	$ 242,553	$ 306,489

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Mr. Jason W. Lettmann
WEBSITE	alxoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	72

ALX Oncology Holdings Inc. Frequently Asked Questions

What is the ticker symbol for ALX Oncology Holdings Inc.? What does ALXO stand for in stocks?

ALXO is the stock ticker symbol of ALX Oncology Holdings Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ALX Oncology Holdings Inc. (ALXO)?

As of Thu May 02 2024, market cap of ALX Oncology Holdings Inc. is 833.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers.

What is the fair value of ALXO stock?

You can check ALXO's fair value in chart for subscribers. The fair value of ALX Oncology Holdings Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ALX Oncology Holdings Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALXO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ALX Oncology Holdings Inc. a good stock to buy?

The fair value guage provides a quick view whether ALXO is over valued or under valued. Whether ALX Oncology Holdings Inc. is cheap or expensive depends on the assumptions which impact ALX Oncology Holdings Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALXO.

What is ALX Oncology Holdings Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ALXO's PE ratio (Price to Earnings) is -5.18 and Price to Sales (PS) ratio is 689.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALXO PE ratio will change depending on the future growth rate expectations of investors.